TRIL - トリリウム・セラピュ―ティクス (Trillium Therapeutics Inc.)

TRILのニュース

   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review  2020/09/11 12:05:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reacted to results for the half-year) Burning Rock Biotech Ltd (NASDAQ: BNR ) Evofem Biosciences Inc (NASDAQ: EVFM ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) ( reacted to a negative late-stage clinical readout for investigational migraine drug) Stocks In Focus Roche Presents Positive Long-Term Data For Multiple Sclerosis Drug Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) announced …
   Trillium Therapeutics Up 40% On Data From Lead Cancer Candidates, Pfizer Investment  2020/09/09 17:08:08 Benzinga
Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL ) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 that was released after hours Tuesday. What Happened: Preliminary data from the TTI-621 (SIRPa-IgG1 Fc fusion protein) four-part Phase 1 trial in patients with advanced relapsed or refractory hematologic malignancies showed that weekly infusions of up to 1.4 mg/kg are well-tolerated without dose-limiting thrombocytopenia. Platelet decreases occurred on dosing days and recovered in two to four days. The antitumor activity in the 1mg/kg dose includes one partial response and one complete response in six evaluable patients. Two of those patients were bridged to allogeneic transplantation. The enrollment in the 2mg/kg cohort is underway. Preliminary data from … Full story available on Benzinga.com
   Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher  2020/09/09 12:04:00 Benzinga
Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to …
   Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level  2020/07/30 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage…
   Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level  2020/07/30 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage…
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Market Crash 2020 Sequel: Why the Next Wave Could Be Worse  2020/06/13 13:33:15 The Motley Fool Canada
A sequel to the 2020 market crash should not happen at all. The stock market is stabilizing with exciting investment options like the Trillium Therapeutics stock and Ballard Power Systems stock emerging. The post Market Crash 2020 Sequel: Why the Next Wave Could Be Worse appeared first on The Motley Fool Canada .
   Trillium Therapeutics Announces “At-The-Market” Equity Program  2020/05/06 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage…
   Is Trillium Therapeutics (TRIL) Stock Outpacing Its Medical Peers This Year?  2020/03/26 15:30:07 Zacks Investment Research
Is (TRIL) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study  2020/01/24 12:43:17 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: MESO ) Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Soligenix, Inc. (NASDAQ: SNGX ) Syneos Health Inc (NASDAQ: SYNH ) TELA Bio Inc (NASDAQ: TELA ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 23) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Evolus Inc (NASDAQ: EOLS ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Second Sight Medical Products Inc (NASDAQ: EYES ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Therapix Biosciences Ltd – ADR (NASDAQ: TRPX ) Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020 Stocks In Focus Kura Oncology Announces Departure of Chief Medical Officer Kura Oncology said Antonio Gualberto, serving as Head of Development and Chief Medical Officer, will leave to pursue other opportunities.
   Trillium prices common and preferred stock offering; shares +5% premarket  2020/01/23 13:42:52 Seeking Alpha
Trillium Therapeutics (NASDAQ:TRIL) has priced its public offering of 35,731,818 common shares and 1,250,000 Series II Non-Voting Convertible First Preferr
   Trillium Therapeutics: This Underdog In The CD47 Space Is Staging A Comeback  2020/01/22 20:46:14 Seeking Alpha
Shares have lost more than a third of their value since my last update and this one was a loser for us in ROTY's model account in 2018. Corporate update shows t
   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.
   Trillium Therapeutics' stock rockets on heavy volume after an upbeat update on cancer-treatment programs  2020/01/09 19:37:00 MarketWatch
Shares of Trillium Therapeutics Inc. nearly doubled in very active trading Thursday, after the developer of cancer treatments provided an upbeat update on…

calendar